Sickle Cell Gene Therapy Cost Effectiveness Draws Scrutiny At ASH
Executive Summary
According to a study presented at the American Society of Hematology, based on existing gene therapy prices, equitable use of sickle cell disease gene therapy requires expanding into patients who are younger and have less severe disease.
You may also be interested in...
Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
Bluebird Could Find US Tailwind For Zynteglo After ICER Report
The cost-effectiveness watchdog now assumes an upfront $2.1m payment instead of five annual payments. The company switched gears to the US after the TDT gene therapy stumbled in Europe.
Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.